J&J's Janssen: Credence Trial of Invokana Being Stopped Early for Positive Efficacy Findings
July 16 2018 - 05:30PM
Dow Jones News
The Janssen Pharmaceutical Companies of Johnson & Johnson
said Monday they were stopping the Phase 3 Credence clinical trial
of Invokana early based on the achievement of pre-specified
efficacy criteria.
Dr. Vlado Perkovic, co-chair of the company's Credence Steering
Committee, said "We have accepted the advice of the Independent
Data Monitoring Committee to stop the CREDENCE trial early due to
demonstration of efficacy, and look forward to sharing the findings
as soon as possible."
The Credence, or Canagliflozin and Renal Events in Diabetes with
Established Nephropathy Clinical Evaluation clinical trial, was
evaluating "the efficacy and safety of Invokana (canagliflozin)
versus placebo when used in addition to standard of care for
patients with chronic kidney disease and type 2 diabetes," the
company said.
"Invokana has the potential to be the first new therapy in more
than 15 years for slowing the progression of chronic kidney disease
in patients with type 2 diabetes," the company stated.
Company website:
https://www.janssen.com/us
--By Stephen Nakrosis; stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 16, 2018 17:15 ET (21:15 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024